What they came to us with.
A precision-medicine company with no single view of itself. Experiments, samples, projects and revenue all lived in different systems, and off-the-shelf tools could not model their science.
Precede is building a first-in-class liquid biopsy platform that profiles gene expression from plasma, co-founded out of Dana-Farber Cancer Institute and published in Nature Medicine.
How we worked.
Two senior people, embedded across the organisation. No large team, no heavy methodology, in the room with five functions, not gathering requirements from a distance.
We interviewed every function, redesigned their data architecture into a single source of truth, delivered five operational dashboards, and deployed AI directly into the R&D pipeline.
From discovery to delivery.
Listen & map
Stakeholder interviews across every function; processes, files and data flows documented.
Architect
A unified data model replacing fragmented Airtable, CRO sheets, lab notebooks and forecasts.
Ship
Five operational dashboards plus three production ML tools in the R&D workflow.
What it unlocked.
Science the world is watching.
“They gave us visibility we never had, and then they went further. The AI use cases they deployed are genuinely accelerating how fast we can develop new tests.”Sr. Director, Scientific Strategy & OperationsPrecede Biosciences